Biogen Idec Deal Uses GSK Model; Partnerships To Double Pipeline By 2010
Biogen and Idec are applying the GlaxoSmithKline model to the biotech world with their $6.8 bil. merger agreement
Biogen and Idec are applying the GlaxoSmithKline model to the biotech world with their $6.8 bil. merger agreement